title: [High intensity focused ultrasound combined with endocrine therapy in treating prostate cancer].
abstract: OBJECTIVE
  To evaluate the clinical efficacy of high intensity focused ultrasound (HIFU) combined with endocrine therapy in the treatment of patients with prostate cancer.
  
  
  METHODS
  Twenty patients with prostate cancer were treated with extracorporeal HIFU device( model FEP-BY01 ) and androgen ablation, of whom 15 received orchiectomy and 5 LHRH-a. Fourteen patients of the total number were given flutamide in addition to castration.
  
  
  RESULTS
  The mean follow-up was 13.5 months (ranging 6 to approximately 30). Before and after the treatment, the prostate volume, prostate specific antigen (PSA), international prostate symptom score (IPSS) and maximal flow rate (Qmax) of the patients were (36.4 +/- 16.2) ml and (20.6 +/- 11.8) ml (P < 0.05), (32.2 +/- 10.4) ng/ml and (2.4 +/- 0.8) ng/ml (P < 0.01), 20. 5 +/- 6.5 and 13.6 +/- 7.5 (P < 0.05), (10.6 +/- 6.3) ml/s and (14.2 +/- 4.6) ml/s (P < 0.05), respectively. Mild hematuria and pain were noted in 5 and 8 patients respectively, and 1 patient underwent internal urethrotomy with a cold knife because of urethral stricture. er, with minimal complications.
  
  
  CONCLUSIONS
  HIFU combined with endocrine therapy is effective in the treatment of prostate canc-
authors.affiliation: Department of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China. hlx5858@163.com
authors.forename: Li-xin
authors.initials: LX
authors.lastname: Hua
authors.forename: Hong-fei
authors.initials: HF
authors.lastname: Wu
authors.forename: Yuan-geng
authors.initials: YG
authors.lastname: Sui
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Li-xin
authors.initials: LX
authors.lastname: Qian
authors.forename: Ning-hong
authors.initials: NH
authors.lastname: Song
authors.forename: Jie-xiu
authors.initials: JX
authors.lastname: Zhang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005485:Flutamide / Q000627:therapeutic use; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000628:therapy*; D016896:Treatment Outcome; D036761:Ultrasound, High-Intensity Focused, Transrectal
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone; D005485:Flutamide